Microcap bioresearch firm Adventrx Pharmaceuticals (ANX -1.1%) is lower today after the FDA says...


Microcap bioresearch firm Adventrx Pharmaceuticals (ANX -1.1%) is lower today after the FDA says the company will need to repeat a study of its lung-cancer treatment Exelbine because it can't verify the authenticity of certain drugs in the previous trial. The shares have been pummeled this year, down nearly 78% since mid-July.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs